Evidence map›Paper›PMID 42253351›Full record

ArticleBlood cell therapy2026

Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India.

Nishant Jindal, Anant Gokarn, Malini Garg, Komal Kumbhalwar, Selma D Silva, Meenakshi Singh, Sadhana Kannan, Libin Jacob Mathew, Sumeet Mirgh, Akanksha Chichra and 5 more

Abstract read
In one paragraph

Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nishant JindalDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Anant GokarnDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Malini GargDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Komal KumbhalwarDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Selma D SilvaHomi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, India.
Meenakshi SinghHomi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, India.
Sadhana KannanHomi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, India.
Libin Jacob MathewDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Sumeet MirghDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Akanksha ChichraDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Lingaraj NayakDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Avinash BondaDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Sachin PunatarDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Bhausaheb BagalDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
Navin KhattryDepartment of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Outcomes of haploidentical transplantation have been reported to be comparable to HLA-matched transplants in several studies; however, data from low- and middle-income countries remain limited. In this retrospective study, we evaluated outcomes of 71 patients who underwent haploidentical transplantation for malignant indications using post-transplant cyclophosphamide (PTCy) between July 2010 and March 2022 and analyzed donor factors influencing outcomes. All patients received peripheral blood stem cell grafts with standard PTCy/calcineurin inhibitor/mycophenolate mofetil prophylaxis. Graft failure occurred in seven patients (9.8%), with a higher incidence observed in those with 0-1 mismatch in the graft versus host direction (

Indexed as

Donor factorsHaploidentical TransplantsOutcomesPTCY

Identifiers

PMID42253351
PMCPMC13237442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.